 The goal of this clinical research study is to learn if bevacizumab, when given in combination with gemcitabine, docetaxel, melphalan and carboplatin, or with topotecan, cyclophosphamide and melphalan if you are older than 60 or have an allergy to carboplatin, can help to control ovarian cancer during a stem cell transplant. The safety of this drug combination will also be studied. 